港股異動 | 百度漲4% “文心一言”已有400多家頭部企業加入 瑞信上調其目標價至171港元
格隆匯2月27日丨百度(9888.HK)盤中漲4.57%,報137.4港元,總市值3798億港元。2月23日,百度副總裁李碩表示,百度的生成式AI產品“文心一言”很快就會推出。據悉,目前已經有包括互聯網、媒體、金融、保險、汽車、企業軟件等行業的400多家頭部企業宣佈加入百度“文心一言”生態。瑞信發研報指,百度核心搜索收入同比下降6%,勝於預期;由於銷售活動中斷,雲業務在LFL的基礎上增加4%;經調整核心營運利潤率為21%,略高於該行及市場預期。該行指,即將推出的聊天機器人和潛在回購為催化劑,目標價上調至171港元,維持跑贏大市評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.